Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
Sumitomo Dainippon Pharma suffered a plunge of over 50% in the first half of FY2018 as its Japan revenue was battered by the April 2018 drug price revision and relentless generic inroads, the company said on October 30. In April-September,…
To read the full story
Related Article
- Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
May 13, 2019
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit
April 19, 2018
- Sumitomo Dainippon Sues 15 More Companies over Latuda Patent
February 27, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
BUSINESS
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
- Astellas Doubles Labor Productivity Since FY2020, Credits Organization Rejig
February 27, 2026
- Sumitomo Regains DSP-0187 Rights as Jazz Calls Off Deal
February 27, 2026
- Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
- Daiichi Sankyo Chair Manabe to Step Down in June
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…